Kiora Pharmaceuticals (KPRX) Cash from Financing Activities (2014 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Cash from Financing Activities came in at -$842.0 in Q1 2026, down 384.46% on a QoQ basis from $296.0 in Q4 2025.
Kiora Pharmaceuticals (KPRX) Cash from Financing Activities (2014 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 13 years of Cash from Financing Activities data on file, last reported at -$842.0 in Q1 2026.
- Quarterly Cash from Financing Activities changed N/A year-over-year to -$842.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $264813.0 (up 5.7% YoY) and the FY2025 annual result came in at $265655.0, down 98.29% from the prior year.
- Cash from Financing Activities retreated to -$842.0 in Q1 2026, from $296.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $15.2 million in Q1 2024 to a low of -$486421.0 in Q4 2023.
- A 5-year average of $3.0 million and a median of $389267.0 in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities tumbled 115.0% — and 2024, when it jumped 2871.23%.
- Tracing KPRX's Cash from Financing Activities over 5 years: stood at $3.2 million in 2022, then plunged by 115.0% to -$486421.0 in 2023, then jumped by 151.5% to $250523.0 in 2024, then plunged by 99.88% to $296.0 in 2025, then tumbled by 384.46% to -$842.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$842.0 (Q1 2026), $296.0 (Q4 2025), and $265359.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Kiora Pharmaceuticals | 15.64 Mn | 15.64 Mn | - | 4.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.92 Mn |
| Jun 30, 2026 | 4.92 Mn |
| Mar 31, 2026 | -842.00 |
| Mar 31, 2026 | -842.00 |
| Dec 31, 2025 | 296.00 |
| Dec 31, 2025 | 296.00 |
| Jun 30, 2025 | 265,359.00 |
| Jun 30, 2025 | 265,359.00 |
| Jun 30, 2024 | 250,523.00 |
| Jun 30, 2024 | 250,523.00 |
| Mar 31, 2024 | 15.25 Mn |
| Mar 31, 2024 | 15.25 Mn |
| Dec 31, 2023 | -486,421.00 |
| Dec 31, 2023 | -486,421.00 |
| Jun 30, 2023 | 5.94 Mn |
| Jun 30, 2023 | 5.94 Mn |
| Mar 31, 2023 | 513,175.00 |
| Mar 31, 2023 | 513,175.00 |
| Dec 31, 2022 | 3.24 Mn |
| Dec 31, 2022 | 3.24 Mn |